Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2018-08-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the use of IRX5183 in 1) patients with relapsed
and/or refractory AML and 2) patients with high-risk MDS or chronic myelomonocytic leukemia
(CMML).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins